-
1 Comment
Kyowa Kirin Co., Ltd is currently in a long term uptrend where the price is trading 83.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.6.
Kyowa Kirin Co., Ltd's total revenue rose by 5.0% to $84B since the same quarter in the previous year.
Its net income has dropped by 11.4% to $10B since the same quarter in the previous year.
Finally, its free cash flow fell by 58.5% to $5B since the same quarter in the previous year.
Based on the above factors, Kyowa Kirin Co., Ltd gets an overall score of 3/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | JP3256000005 |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Market Cap | 7B |
---|---|
PE Ratio | 19.14 |
Target Price | None |
Dividend Yield | 2.8% |
Beta | 0.18 |
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis; Kura Oncology, Inc to develop and commercialize Ziftomenib in acute leukemias; and Cimeio Therapeutics to develop a novel therapy for diseases with high unmet need. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for KY4.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025